A clinical trial that gives drugs for one type of cancer to patients with another type of cancer may seem like a mix-and-match approach, but it’s actually a highly focused precision medicine initiative.
The NCI-Molecular Analysis for Therapy Choice (NCI-MATCH) trial assigns drugs according to the genetic abnormalities of cancer cells instead of the organ where the cancer originates. It aims to identify new treatments for patients who otherwise might be running out of options.
To qualify for the clinical trial, adult patients must have cancers with one of a series of targeted genetic abnormalities. The drugs in this large and transformative precision medicine trial target those mutations.